flutamide has been researched along with Adrenal Hyperplasia, Congenital in 7 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Adrenal Hyperplasia, Congenital: A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone." | 9.09 | Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000) |
| "The aim of this study was to examine the contribution of flutamide to circulating antiandrogenic activity in children with congenital adrenal hyperplasia using a recombinant cell bioassay." | 7.73 | Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment. ( Dunkel, L; Hero, M; Jänne, OA; Näntö-Salonen, K; Raivio, T, 2005) |
| "Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both." | 6.68 | A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996) |
| "Flutamide treatment decreases cortisol clearance, thereby prolonging its half-life." | 5.31 | Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ( Brook, CG; Charmandari, E; Hindmarsh, PC; Honour, JW; Johnston, A, 2002) |
| "Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency is characterized by a defect in cortisol and aldosterone secretion and adrenal hyperandrogenism." | 5.31 | Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. ( Calis, KA; Charmandari, E; Keil, MF; Merke, DP; Mohassel, MR; Remaley, A, 2002) |
| " We previously reported better control of linear growth, weight gain, and bone maturation in a short term cross-over study of a new four-drug treatment regimen containing an antiandrogen (flutamide), an inhibitor of androgen to estrogen conversion (testolactone), reduced hydrocortisone dose, and fludrocortisone, compared to the effects of a control regimen of hydrocortisone and fludrocortisone." | 5.09 | Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000) |
| "The aim of this study was to examine the contribution of flutamide to circulating antiandrogenic activity in children with congenital adrenal hyperplasia using a recombinant cell bioassay." | 3.73 | Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment. ( Dunkel, L; Hero, M; Jänne, OA; Näntö-Salonen, K; Raivio, T, 2005) |
| "Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both." | 2.68 | A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996) |
| "Flutamide treatment decreases cortisol clearance, thereby prolonging its half-life." | 1.31 | Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ( Brook, CG; Charmandari, E; Hindmarsh, PC; Honour, JW; Johnston, A, 2002) |
| "Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency is characterized by a defect in cortisol and aldosterone secretion and adrenal hyperandrogenism." | 1.31 | Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. ( Calis, KA; Charmandari, E; Keil, MF; Merke, DP; Mohassel, MR; Remaley, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azarchi, S | 1 |
| Bienenfeld, A | 1 |
| Lo Sicco, K | 1 |
| Marchbein, S | 1 |
| Shapiro, J | 1 |
| Nagler, AR | 1 |
| Hero, M | 1 |
| Jänne, OA | 1 |
| Näntö-Salonen, K | 1 |
| Dunkel, L | 1 |
| Raivio, T | 1 |
| Laue, L | 1 |
| Merke, DP | 4 |
| Jones, JV | 2 |
| Barnes, KM | 1 |
| Hill, S | 2 |
| Cutler, GB | 3 |
| Keil, MF | 2 |
| Fields, J | 1 |
| Charmandari, E | 2 |
| Johnston, A | 1 |
| Honour, JW | 1 |
| Brook, CG | 1 |
| Hindmarsh, PC | 1 |
| Calis, KA | 1 |
| Mohassel, MR | 1 |
| Remaley, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia[NCT00529841] | 7 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flutamide and Adrenal Hyperplasia, Congenital
| Article | Year |
|---|---|
Androgens in women: Hormone-modulating therapies for skin disease.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant | 2019 |
2 trials available for flutamide and Adrenal Hyperplasia, Congenital
| Article | Year |
|---|---|
A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Bone Dev | 1996 |
Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Anti-Inflammatory Agents; Antineop | 2000 |
4 other studies available for flutamide and Adrenal Hyperplasia, Congenital
| Article | Year |
|---|---|
Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment.
Topics: Administration, Oral; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Biological A | 2005 |
New approaches to the treatment of congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Age Determination by Skeleton; Androgen Antagonists; Child; Cyprote | 1997 |
Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia.
Topics: Adolescent; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Anti-Inflammatory Agents; Area Un | 2002 |
Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Child; Cortisone; Dose-Response Relationship, | 2002 |